These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 27605552

  • 1. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M.
    Sci Transl Med; 2016 Sep 07; 8(355):355ra117. PubMed ID: 27605552
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.
    Oncotarget; 2015 Oct 13; 6(31):30487-99. PubMed ID: 26431162
    [Abstract] [Full Text] [Related]

  • 3. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
    Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ.
    Leukemia; 2012 Apr 13; 26(4):788-94. PubMed ID: 22033489
    [Abstract] [Full Text] [Related]

  • 4. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 13; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 5. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Leukemia; 2017 Oct 13; 31(10):2065-2074. PubMed ID: 28321124
    [Abstract] [Full Text] [Related]

  • 6. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O, Kuepper MK, Bütow M, Costa IG, Appelmann I, Beier F, Luedde T, Braunschweig T, Koschmieder S, Brümmendorf TH, Schemionek M.
    BMC Cancer; 2019 Jul 04; 19(1):658. PubMed ID: 31272418
    [Abstract] [Full Text] [Related]

  • 7. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A, Buckle AM, Hiwarkar P, Syed F.
    PLoS One; 2015 Jul 04; 10(4):e0123016. PubMed ID: 25849484
    [Abstract] [Full Text] [Related]

  • 8. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.
    Biochem Biophys Res Commun; 2016 Apr 15; 472(4):610-6. PubMed ID: 26966074
    [Abstract] [Full Text] [Related]

  • 9. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z, Liu T, Zhang J.
    Biochem Biophys Res Commun; 2019 Dec 10; 520(3):560-565. PubMed ID: 31615652
    [Abstract] [Full Text] [Related]

  • 10. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
    Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M.
    Haematologica; 2020 May 10; 105(5):1274-1284. PubMed ID: 31371419
    [Abstract] [Full Text] [Related]

  • 11. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M.
    Oncogene; 2014 Oct 16; 33(42):5028-38. PubMed ID: 24747972
    [Abstract] [Full Text] [Related]

  • 12. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.
    Mol Cancer Ther; 2009 Sep 16; 8(9):2509-16. PubMed ID: 19723894
    [Abstract] [Full Text] [Related]

  • 13. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.
    Cancer Res; 2013 Sep 15; 73(18):5775-86. PubMed ID: 23887971
    [Abstract] [Full Text] [Related]

  • 14. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.
    Blood; 2008 Mar 01; 111(5):2843-53. PubMed ID: 18156496
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.